AOD-9604: HGH Fragment, Fat Metabolism & Cartilage Research Guide

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic modified peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176-191. It was developed at Monash University in Melbourne, Australia, by Professor Frank Ng’s research group in the late 1990s, based on the observation that the fat-reducing effects of growth hormone could be separated from its growth-promoting and diabetogenic effects by isolating specific regions of the GH molecule.

The key structural modification in AOD-9604 is the addition of a tyrosine residue at the N-terminus of the HGH 176-191 fragment, creating a 16-amino-acid peptide that retains the lipolytic (fat-mobilizing) activity of growth hormone without the growth-promoting effects mediated by IGF-1 signaling. This separation of functions was a deliberate design goal: the researchers sought a compound that could promote fat metabolism without the hyperglycemia, insulin resistance, and tissue growth effects associated with full-length GH administration.

AOD-9604 has undergone significant clinical development, including phase IIb clinical trials in humans for obesity, and has received regulatory attention from both the FDA and Australian TGA. It is one of the few research peptides in the metabolic space with substantial human clinical data, which provides a stronger evidence base than most peptides rely upon.

How AOD-9604 Works: Mechanism of Action

AOD-9604’s mechanism of action involves the lipolytic signaling pathways originally identified in the C-terminal fragment of growth hormone, with several key distinctions from full-length GH signaling:

• Beta-3 adrenergic receptor pathway — AOD-9604 has been shown to stimulate lipolysis through activation of the beta-3 adrenergic receptor (β3-AR) pathway in adipose tissue. This pathway activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), the enzymes responsible for mobilizing stored triglycerides into free fatty acids and glycerol for energy metabolism.
• Fat oxidation enhancement — Beyond mobilizing fatty acids from adipose stores, AOD-9604 has been shown to enhance the oxidation (burning) of those fatty acids. Research has documented increased fat oxidation rates in treated adipose tissue explants and in vivo models, indicating that the mobilized fat is directed toward energy production rather than simply being re-esterified.
• Lipogenesis inhibition — AOD-9604 has demonstrated inhibitory effects on de novo lipogenesis — the process of converting carbohydrates and other substrates into new fat. This dual mechanism (enhanced lipolysis + inhibited lipogenesis) creates a net negative fat balance in treated tissues.
• No IGF-1 stimulation — Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor in a manner that activates the JAK2-STAT5 signaling cascade responsible for IGF-1 production. This means it does not promote tissue growth, does not cause the insulin resistance associated with GH-induced IGF-1 elevation, and does not carry the theoretical concerns associated with chronically elevated IGF-1 levels.
• No effect on blood glucose — Clinical studies have confirmed that AOD-9604 does not cause the hyperglycemia or insulin resistance associated with GH therapy. Blood glucose, insulin levels, and HOMA-IR (a measure of insulin resistance) remained unchanged in human clinical trials at all doses tested.
• Cartilage-specific mechanisms — More recently, AOD-9604 has been investigated for effects on cartilage cells (chondrocytes). Research has shown that the peptide stimulates proteoglycan and collagen synthesis in cartilage tissue, potentially through mechanisms independent of its lipolytic activity. This unexpected finding has opened a second major research avenue for AOD-9604.

Relationship to HGH Fragment 176-191

AOD-9604 and HGH Fragment 176-191 are closely related but not identical compounds:

• HGH Fragment 176-191 — The unmodified C-terminal fragment of human growth hormone, consisting of amino acids 176 through 191. This is the native sequence found in the GH molecule.
• AOD-9604 — HGH Fragment 176-191 with an additional N-terminal tyrosine residue and a disulfide bond modification. These structural changes enhance stability and bioactivity compared to the unmodified fragment.

Both peptides target the same lipolytic pathways, but AOD-9604’s structural modifications give it improved pharmacological properties. Research comparing the two has generally shown AOD-9604 to have greater potency and stability, though both remain subjects of active investigation.

Clinical Trial Data

Phase IIb Obesity Trial

The most significant clinical evidence for AOD-9604 comes from a phase IIb clinical trial conducted by Metabolic Pharmaceuticals (now Calzada Ltd.) involving 300 obese subjects. The randomized, double-blind, placebo-controlled trial evaluated oral AOD-9604 at doses of 1 mg, 5 mg, and 20 mg daily for 12 weeks. Key findings:

• Dose-dependent weight loss — Subjects in the 1 mg group showed the greatest mean weight loss, with statistically significant reductions compared to placebo at the 12-week endpoint
• Fat-specific loss — DEXA scan analysis indicated that weight changes were primarily attributable to fat mass reduction rather than lean mass or water loss
• No metabolic adverse effects — No changes in blood glucose, insulin, IGF-1, or other metabolic parameters. This confirmed the preclinical finding that AOD-9604’s lipolytic effects were decoupled from GH’s metabolic side effects
• Good tolerability — Adverse event rates were comparable to placebo, with no dose-limiting toxicities identified

Limitations of the Clinical Program

Despite positive phase IIb results, the AOD-9604 clinical development program did not advance to phase III trials. Several factors contributed:

• The effect size, while statistically significant, was modest — an issue common to many anti-obesity compounds
• The FDA issued a non-approvable letter citing insufficient efficacy data to support approval
• The competitive landscape for obesity therapeutics shifted toward GLP-1 receptor agonists (semaglutide, tirzepatide), which demonstrated much larger effect sizes

The discontinuation of the obesity program does not invalidate the clinical safety and mechanistic data generated — it reflects the commercial reality of obesity drug development rather than a safety or efficacy failure.

Pharmacokinetic Data

• Oral bioavailability — Demonstrated oral activity in clinical trials, which is unusual for peptides. The relatively small size and structural modifications contribute to gastrointestinal stability.
• Half-life — Relatively short, consistent with small peptide kinetics. Multiple daily dosing or sustained-release formulations may optimize exposure.
• No accumulation — Chronic dosing studies did not show evidence of peptide or metabolite accumulation.

Cartilage and Osteoarthritis Research

The discovery of AOD-9604’s effects on cartilage tissue has become the most active area of current research, with significant commercial development activity.

In Vitro Cartilage Studies

Research using human chondrocyte cultures has demonstrated that AOD-9604:

• Stimulates proteoglycan synthesis in a dose-dependent manner
• Enhances type II collagen production — the primary collagen in articular cartilage
• Promotes chondrocyte proliferation
• Reduces the expression of matrix metalloproteinases (MMPs) that degrade cartilage matrix
• Exerts anti-inflammatory effects in cytokine-stimulated chondrocytes

Animal Models of Osteoarthritis

In surgically induced osteoarthritis models (typically anterior cruciate ligament transection or meniscal destabilization in rodents), intra-articular AOD-9604 administration has been associated with:

• Reduced cartilage degeneration scores
• Preserved cartilage thickness
• Lower levels of inflammatory markers in synovial fluid
• Improved joint function on gait analysis

Clinical Development for Musculoskeletal Applications

Based on the preclinical cartilage data, AOD-9604 has been developed into an intra-articular injection formulation for osteoarthritis. The Australian Therapeutic Goods Administration (TGA) granted AOD-9604 novel food status in 2011, and subsequent development has focused on the musculoskeletal space. Clinical trials evaluating intra-articular AOD-9604 for knee osteoarthritis are in progress, representing the most advanced clinical application of this peptide.

Fat Metabolism Research: Detailed Findings

Adipose Tissue Specificity

Research has investigated whether AOD-9604’s lipolytic effects differ across adipose tissue depots. Studies have documented greater effects on visceral (abdominal) fat compared to subcutaneous fat, which is noteworthy because visceral adiposity is more strongly associated with metabolic disease risk. This depot specificity may relate to differences in β3-AR expression density between visceral and subcutaneous fat.

No Tolerance Development

A significant finding from chronic administration studies was the absence of tolerance development. Unlike some lipolytic agents that lose efficacy with repeated administration (potentially through receptor downregulation), AOD-9604 maintained its fat-mobilizing activity throughout extended treatment periods in both animal and human studies.

Comparison with Other Metabolic Peptides

In the context of NorthPeptide’s metabolic research offerings, AOD-9604 occupies a specific niche:

• Retatrutide — A triple-agonist GLP-1/GIP/glucagon receptor peptide with potent appetite suppression and body weight effects. Acts centrally on appetite circuits and peripherally on multiple metabolic pathways. Much larger effect sizes in clinical trials.
• MOTS-c — A mitochondrial-derived exercise mimetic that activates AMPK-mediated fat oxidation. Different mechanism (AMPK vs. β3-AR) from AOD-9604, with less human data but more recent scientific interest.
• 5-Amino-1MQ — A small molecule (not a peptide) that inhibits NNMT, an enzyme involved in nicotinamide metabolism and adipocyte differentiation. Mechanistically distinct from AOD-9604.
• HGH Fragment 176-191 — The unmodified parent fragment of AOD-9604 with the same target pathways but lower potency and stability.

Dosing in Research Models

Research Context	Dose	Route	Duration
Phase IIb obesity trial	1–20 mg/day	Oral	12 weeks
Rodent obesity models	500 μg/kg/day	IP injection	4–12 weeks
Cartilage studies (animal)	10–100 μg per joint	Intra-articular	Single or weekly injections
Adipose tissue explants	1–50 μg/mL	Culture medium	2–24 hours

Reconstitution and Handling

• Storage — Lyophilized AOD-9604 at -20°C for long-term stability
• Reconstitution — Reconstitute with sterile bacteriostatic water. AOD-9604 dissolves readily in aqueous solution.
• Stability — Reconstituted solution stable approximately 20–25 days at 2–8°C
• pH sensitivity — Optimal stability at slightly acidic pH (5.0–6.5). If preparing specific research formulations, consider buffering accordingly.

Safety Profile

AOD-9604 has one of the stronger safety profiles in the research peptide space, supported by human clinical trial data:

• Phase IIb safety — No dose-limiting toxicities at any dose tested (up to 20 mg/day oral for 12 weeks). Adverse events comparable to placebo.
• No metabolic disruption — No effects on glucose, insulin, IGF-1, thyroid function, or other endocrine parameters
• No growth effects — Confirmed absence of growth-promoting activity, addressing the key safety concern associated with full-length GH
• TGA novel food status — The Australian TGA’s classification of AOD-9604 as a novel food in 2011 indicates a favorable safety assessment for oral consumption
• No anti-drug antibodies — Clinical studies did not detect immunogenic responses to AOD-9604

Regulatory Status

AOD-9604 has a complex regulatory history:

• FDA — Received a non-approvable letter for the obesity indication (insufficient efficacy data). Not approved for any indication in the US.
• TGA (Australia) — Classified as a novel food ingredient (2011). Ongoing clinical development for osteoarthritis (intra-articular formulation).
• WADA — Listed under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth hormone fragment, prohibited in athletic competition.
• Research use — Available from research suppliers as a lyophilized peptide for laboratory investigation.

Current Limitations and Future Directions

• Obesity program discontinued — The primary clinical indication was not pursued to approval, limiting the clinical data available for the metabolic application
• Modest effect sizes for weight management — In the context of modern GLP-1 agonists that produce 15–20% body weight reductions, AOD-9604’s more modest effects face a high competitive bar
• Cartilage trials ongoing — The osteoarthritis clinical program represents the most promising near-term clinical application, but definitive results are pending
• Mechanism of cartilage effects unclear — The molecular mechanism through which a GH fragment stimulates chondrocyte function is not fully characterized

Future research directions include the completion of osteoarthritis clinical trials, investigation of combination approaches (AOD-9604 + other metabolic or musculoskeletal peptides), and mechanistic studies to better characterize the cartilage-specific effects.

Summary

AOD-9604 is a modified fragment of human growth hormone that isolates GH’s lipolytic activity without its growth-promoting, hyperglycemic, or IGF-1-elevating effects. Supported by phase IIb clinical trial data demonstrating fat-specific weight loss with an excellent safety profile, it occupies a unique position as one of the few metabolic research peptides with substantial human evidence. The more recent discovery of its cartilage-protective properties has opened a second major research avenue, with clinical trials for osteoarthritis currently in progress. While its obesity development program was discontinued due to modest effect sizes relative to modern therapeutics, the peptide’s decoupled mechanism and clinical safety record continue to support its value as a research tool in metabolic and musculoskeletal science.

View AOD-9604 and HGH Fragment 176-191 in our research catalog.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Heffernan et al.	2001	In Vivo	Effects of hGH and AOD9604 on lipid metabolism in obese mice	PMID 11713213
Ng et al.	2001	In Vivo	Increased fat oxidation and weight loss in obese mice with AOD9604	PMID 11673763
Stier et al.	2000	In Vitro	Metabolic studies of synthetic lipolytic domain AOD9604 of hGH	PMID 11146367
Ng et al.	2000	Clinical Study	Effects of oral administration of hGH fragment on lipid metabolism	PMID 10950816
Ng & Borgeest	1994	In Vitro	Effect of antilipogenic fragment of hGH on glucose transport in adipocytes	PMID 8118430
Greenwood & Wieland	2013	Review	Obesity pharmacotherapy — current perspectives and future directions	PMC3584306
Kwon et al.	2015	In Vivo	Intra-articular injection of AOD9604 in rabbit osteoarthritis model	PMID 26275694
Thomas et al.	2004	Clinical Trial	AOD-9604 metabolic safety and pharmacokinetics in humans	PMID 15134286

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.